SWTX - SpringWorks Therapeutics Inc Stock Price, Fair Value and News

$35.58+0.16 (+0.45%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SWTX RSI Chart

SWTX Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-8.74

Price/Sales (Trailing)

28.59

Price/Free Cashflow

-11.11

SWTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SWTX Fundamentals

SWTX Revenue

Revenue (TTM)

92.0M

Rev. Growth (Yr)

946.3%

Rev. Growth (Qtr)

184.36%

SWTX Earnings

Earnings (TTM)

-301.1M

Earnings Growth (Yr)

48.77%

Earnings Growth (Qtr)

54.32%

SWTX Price Action

Last 7 days

-9%

Last 30 days

-2.6%

Last 90 days

-2.2%

Trailing 12 Months

38.2%

SWTX Profitability

Return on Equity

-54.08%

Return on Assets

-48.77%

Free Cashflow Yield

-9%

SWTX Financial Health

Current Ratio

7.91

SWTX Investor Care

Shares Dilution (1Y)

18.70%

Diluted EPS (TTM)

-4.44

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	57.5M	92.0M	0	0
2023	11.7M	15.5M	19.2M	22.9M
2022	1.9M	3.3M	4.7M	6.1M
2021	26.4M	17.8M	9.2M	546.0K
2020	0	3.1M	2.2M	35.0M
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

CEO	Mr. Saqib Islam J.D.
WEBSITE	springworkstx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	227

SpringWorks Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for SpringWorks Therapeutics Inc? What does SWTX stand for in stocks?

SWTX is the stock ticker symbol of SpringWorks Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SpringWorks Therapeutics Inc (SWTX)?

As of Tue Sep 17 2024, market cap of SpringWorks Therapeutics Inc is 2.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SWTX stock?

You can check SWTX's fair value in chart for subscribers.

Is SpringWorks Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SWTX is over valued or under valued. Whether SpringWorks Therapeutics Inc is cheap or expensive depends on the assumptions which impact SpringWorks Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SWTX.

What is SpringWorks Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Sep 17 2024, SWTX's PE ratio (Price to Earnings) is -8.74 and Price to Sales (PS) ratio is 28.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SWTX PE ratio will change depending on the future growth rate expectations of investors.